Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mace L Rothenberg

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Oncology (Williston Park, N.Y.)|January 11, 2003
Current status of capecitabine in the treatment of colorectal cancerMace L Rothenberg
Clinical Colorectal Cancer|June 24, 2004
Current status of second-line therapy for metastatic colorectal cancerMace L Rothenberg
Current Oncology Reports|April 2, 2003
Chemotherapeutic advances in pancreatic cancerJordan D Berlin, Mace L Rothenberg
Cancer Journal (Sudbury, Mass.)|August 1, 2020
Price, Cost, and Value of Cancer Medicines: A Pharmaceutical Industry PerspectiveMace L Rothenberg, Justin McCarthy, Patrick Holmes
Oncology Reports|September 14, 2006
A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patientsYair Gazitt, Paul Shaughnessy, Mace L Rothenberg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2007
Intraperitoneal chemotherapy for ovarian cancer: overview and perspectiveGautam Rao, Marta Crispens, Mace L Rothenberg
Nature Reviews. Cancer|April 3, 2003
Improving the evaluation of new cancer treatments: challenges and opportunitiesMace L Rothenberg, David P Carbone, David H Johnson
Gastroenterology|May 12, 2005
Treatment for pancreatic cancer: current therapy and continued progressA Craig Lockhart, Mace L Rothenberg, Jordan D Berlin
The Oncologist|February 15, 2005
Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug developmentWooin Lee, A Craig Lockhart, Richard B Kim, et al.
Clinical Colorectal Cancer|February 11, 2009
Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON IIIJane D Robertson, Nick A Botwood, Mace L Rothenberg, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Oncology (Williston Park, N.Y.)|January 11, 2003
Current status of capecitabine in the treatment of colorectal cancerMace L Rothenberg
Clinical Colorectal Cancer|June 24, 2004
Current status of second-line therapy for metastatic colorectal cancerMace L Rothenberg
Current Oncology Reports|April 2, 2003
Chemotherapeutic advances in pancreatic cancerJordan D Berlin, Mace L Rothenberg
Cancer Journal (Sudbury, Mass.)|August 1, 2020
Price, Cost, and Value of Cancer Medicines: A Pharmaceutical Industry PerspectiveMace L Rothenberg, Justin McCarthy, Patrick Holmes
Oncology Reports|September 14, 2006
A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patientsYair Gazitt, Paul Shaughnessy, Mace L Rothenberg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2007
Intraperitoneal chemotherapy for ovarian cancer: overview and perspectiveGautam Rao, Marta Crispens, Mace L Rothenberg
Nature Reviews. Cancer|April 3, 2003
Improving the evaluation of new cancer treatments: challenges and opportunitiesMace L Rothenberg, David P Carbone, David H Johnson
Gastroenterology|May 12, 2005
Treatment for pancreatic cancer: current therapy and continued progressA Craig Lockhart, Mace L Rothenberg, Jordan D Berlin
The Oncologist|February 15, 2005
Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug developmentWooin Lee, A Craig Lockhart, Richard B Kim, et al.
Clinical Colorectal Cancer|February 11, 2009
Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON IIIJane D Robertson, Nick A Botwood, Mace L Rothenberg, et al.
Pageof 6